Strand Life Sciences, a Bengaluru-based subsidiary of Reliance Industries Restricted, on Tuesday (7 July 2026) introduced the granting of an Indian patent masking an built-in platform for early most cancers detection utilizing cell-free DNA (cfDNA) evaluation.
In line with the official communiqué, the patented platform integrates high-quality sequencing, rigorous high quality management, biologically knowledgeable methylation and fragmentary function extraction, and machine studying to allow most cancers detection and tissue-of-origin prediction from only a blood pattern.
The patent covers a cell-free DNA evaluation platform that permits early detection of most cancers via blood checks. Alterations in widespread methylation patterns throughout the genome are an indicator of most cancers. In line with the corporate, the patent’s key innovation makes use of genome sequencing to seize these methylation patterns with minimal loss or failure, enabling extremely delicate early most cancers detection.
It’s estimated that greater than 1.5 million new most cancers instances happen yearly, however sadly many sufferers are nonetheless identified at a sophisticated stage, therapy choices are restricted, and outcomes are considerably poorer. Early detection can transfer the analysis to an earlier stage. By decreasing the price of sequencing, the patented platform has the potential to allow early detection at scale with out increasing native infrastructure, the corporate claimed.
“This patent displays our dedication to growing a scientifically rigorous, AI-enabled liquid biopsy know-how that may detect most cancers early from a easy blood pattern. We consider this innovation is a vital step towards making precision most cancers screening extra correct, scalable, and accessible,” stated Ramesh Hariharan, CEO of Strand Lifesciences.
